Inactive Instrument

Other languages Endologix, Inc.

Equities

ELGXQ

US29266S3040

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Endologix LLC Appoints Graham Phillips as Chief Operating Officer	06-18
Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery	05-13
Endologix LLC Appoints Mike Mathias as Chief Commercial Officer	03-05
Endologix LLC Announces That Art Taylor Joins Board of Directors	01-25
Endologix LLC Appoints Scott Ward Joins Board of Directors	01-09
Endologix LLC Announces Appointment of Scott Ward as Board of Directors	01-09
Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System	12-27
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session	11-02
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System	23-09-07
Endologix LLC Appoints Lucas Buchanan to its Board of Directors	23-08-24
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease	23-07-18
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting	23-06-15
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad	23-06-08
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial	23-05-23
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session	22-11-11
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial	22-11-03
Endologix LLC Announces the Elevate	22-10-20
Endologix LLC Submits Premarket Approval Application to FDA for the DETOUR System	22-10-10
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting	22-06-23
Endologix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Endologix, Inc.

Equities

ELGXQ

US29266S3040

Other languages

Filters